Pharming Group N.V. (PHAR)

NASDAQ: PHAR · IEX Real-Time Price · USD
11.75
0.00 (0.00%)
At close: Feb 22, 2024, 12:00 AM
11.39
-0.36 (-3.06%)
After-hours: Feb 23, 2024, 4:00 PM EST
0.00%
Market Cap 788.51M
Revenue (ttm) 232.68M
Net Income (ttm) -23.46M
Shares Out 67.11M
EPS (ttm) -0.35
PE Ratio n/a
Forward PE 169.49
Dividend n/a
Ex-Dividend Date n/a
Volume 95
Open 11.13
Previous Close 11.75
Day's Range 11.13 - 12.00
52-Week Range 9.65 - 17.81
Beta 0.76
Analysts Strong Buy
Price Target 38.50 (+227.66%)
Earnings Date Mar 14, 2024

About PHAR

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous he... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1988
Employees 332
Stock Exchange NASDAQ
Ticker Symbol PHAR
Full Company Profile

Financial Performance

In 2022, Pharming Group's revenue was 205.62 million, an increase of 3.39% compared to the previous year's 198.87 million. Earnings were 13.67 million, a decrease of -14.52%.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for PHAR stock is "Strong Buy." The 12-month stock price forecast is $38.5, which is an increase of 227.66% from the latest price.

Price Target
$38.5
(227.66% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Pharming Group to participate in February investor conferences

Leiden, The Netherlands, February 8, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor con...

17 days ago - GlobeNewsWire

Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update

Expect 10% growth in RUCONEST® revenue, significantly exceeding prior guidance Expect Joenja® revenues of approximately US$18 million with 81 patients on paid therapy at year end Leiden, The Netherlan...

6 weeks ago - GlobeNewsWire

Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)

Initial development in PIDs with immune dysregulation linked to PI3Kẟ signaling Phase 2 clinical trial initiation planned for 2 Q 2024 Leiden, The Netherlands, December 13, 2023: Pharming Group N.V. (...

2 months ago - GlobeNewsWire

Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval

Leiden, The Netherlands, November 10, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has received a Day 180 Second List of Outstandi...

3 months ago - GlobeNewsWire

Pharming Group announces presentations at International Primary Immunodeficiencies Congress and the American College of Allergy, Asthma & Immunology Annual Scientific Meeting

Leiden, The Netherlands, November 7, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces 14 poster presentations by the Company or its collaborat...

3 months ago - GlobeNewsWire

Pharming Group to participate in November investor conferences

Leiden, The Netherlands, November 1, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor con...

4 months ago - GlobeNewsWire

Pharming Group reports third quarter 2023 financial results

Pharming Group reports third quarter 2023 financial results Third quarter 2023 revenues increased 23% to US$66.7 million, compared to the third quarter 2022, driven by RUCONEST® revenue and the U.S. c...

4 months ago - GlobeNewsWire

Pharming Group to report third quarter 2023 financial results on October 26

Leiden, The Netherlands, October 12, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2023 financial re...

4 months ago - GlobeNewsWire

Pharming Group reports on results of the 2023 Extraordinary General Meeting of Shareholders

Leiden, The Netherlands, September 25, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of Shareholders (EG...

5 months ago - GlobeNewsWire

Pharming Group to participate in September investor conferences

LEIDEN, The Netherlands , Aug. 24, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following...

6 months ago - PRNewsWire

Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan

Single-arm Phase III study in Japan evaluating leniolisib in patients aged 12 years and older with APDS, a rare primary immunodeficiency LEIDEN, The Netherlands , Aug. 9, 2023 /PRNewswire/ -- Pharming...

7 months ago - PRNewsWire

Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board

LEIDEN, The Netherlands , July 18, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has nomin...

7 months ago - PRNewsWire

Pharming Group to report second quarter and first half 2023 financial results on August 3

LEIDEN, The Netherlands , July 13, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter and...

8 months ago - PRNewsWire

Pharming announces sale of priority review voucher

LEIDEN, The Netherlands , June 1, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has entered into a definitive agreem...

9 months ago - PRNewsWire

Pharming Group to attend the following Investor Conferences in June

LEIDEN, The Netherlands , May 25, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will attend the following investor...

9 months ago - PRNewsWire

Pharming Group reports financial results for the first quarter of 2023

FDA approval and commercial launch of Joenja® (leniolisib) in the U.S. Joenja® launch off to strong start with 23 U.S. patients on paid therapy Revenues decreased by 9% to US$42.5 million, compared to...

10 months ago - PRNewsWire

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

LEIDEN, Netherlands , April 11, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) announces the first commercial shipments of Joenja® (leniolisib) to pat...

11 months ago - PRNewsWire

Pharming to present at the Guggenheim Healthcare Talks - Genomic Medicines and Rare Disease Days

LEIDEN, The Netherlands , March 30, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's Chief Executive Officer, Sijmen de Vries, a...

11 months ago - PRNewsWire

Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS

APDS (activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome) is a rare and progressive primary immunodeficiency Joenja® is a targeted treatment of APDS for adult and pediatric patients 12 years o...

1 year ago - PRNewsWire

Pharming announces first patient enrolled in pediatric clinical trial of leniolisib

The multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency LEIDEN, Netherlands , Feb. 21, 2023 /PRNewswire/ -- Pharmin...

1 year ago - PRNewsWire

Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe

EMA Marketing Authorisation Application for leniolisib changed to standard review timetable LEIDEN, Netherlands , Feb. 16, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURON...

1 year ago - PRNewsWire

Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

V. Koneti Rao, MD, shared new evidence of long-term safety and hematologic response in patients who received leniolisib to treat APDS, a rare primary immunodeficiency Interim analysis demonstrated len...

1 year ago - PRNewsWire

Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood

Leniolisib was well tolerated and significant improvement over placebo was notable in the co-primary endpoints, reflecting a favorable impact on patients' immune dysregulation and deficiency The peer-...

1 year ago - PRNewsWire

Pharming Group announces presentation of new leniolisib data at 2022 ASH Annual Meeting

Presentation to highlight data from the ongoing long-term open-label extension study of leniolisib, a PI3Kδ inhibitor under investigation for APDS, a rare primary immunodeficiency LEIDEN, Netherlands ...

1 year ago - PRNewsWire

Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib

Marketing authorisation in the European Economic Area anticipated in H1 2023 LEIDEN, Netherlands , Oct. 28, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: ...

1 year ago - PRNewsWire